Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
Follow ZBH
Alert me
Zimmer Biomet Holdings, Inc. 10-Q filed Nov 4, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 3 added · 3 removed · 32 modified; 4 with only figures updated
-
Modified · Results for the Three and Nine-Month Periods ended September 30, 2026
In the three and
six-monthnine-month periods endedJuneSeptember 30, 2026, our net sales increased4.83.1 percent and7.05.7 percent, respectively, when compared to the same prior year periods. Net sales growth was driven by a combination ofour Paragon 28 acquisition, positive effects of changesopportunistic end-of-quarter customer purchases; the 2026 acquisitions; growth inforeign currency exchange rates, opportunistic end-of-quarter customer purchasessales of our foot and ankle,increasedROSA® Robot and bone cementsales,products; market growth; and new product introductions. In addition, Paragon 28 had a positive impact on our net sales of0.71.5 percentand 2.3 percentin thethree and six-month periodsnine-month period endedJuneSeptember 30, 2026, respectively. Additionally, our net sales experienced apositivenegative effect of0.10.6 percent and1.3a positive effect of 0.7 percent from changes in foreign currency exchange rates in the three andsix-monthnine-month periods endedJuneSeptember 30, 2026, respectively.